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Drug-eluting stents (DES) have revolutionized interven-
tional cardiology and have fueled vascular research. How-
ever, not all DES are created equal, and recently, second-
generation DES became available (1–4). Some esteemed
basic and clinical cardiovascular investigators openly argue
that simply comparing stent “A” with stent “B” should not
be considered as proper research. Although the value of this
criticism should not be completely dismissed, the other side
of the same coin is that clinical research should actually
focus on improving patient care. In this regard, the poten-
tially superior results of novel devices in the clinical arena
should not be taken for granted, based on promising bench
findings or surrogate endpoints, but rather carefully scruti-
nized and confirmed in rigorous clinical studies with robust
methodology and long-term follow-up (1–4).
See pages 11 and 19
Interventional cardiology provides a tempting scenario for
love at first sight with never-ending novel, highly attractive
devices. Experience, however, consistently demonstrates that
great expectations may soon vanish and also that improving
patients’ clinical prognosis tends to be much harder than
initially anticipated. With a wide array of DES currently
available, many scientific (and nonscientific) issues are consid-
ered in the catheterization laboratory during the decision-
making-process involved in device selection. Quite recently we
learned our lesson after embracing a rather liberal use of
first-generation DES, pursuing their unprecedented late an-
giographic results (5). Therefore, we should avoid leaps of faith
and stumbling over the same stone again. Critical skepticism
on DES metamorphosis should temper the overriding enthu-
siasm generated by the newest devices.
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DES that elute everolimus (rapamycin analog) from a thin
biocompatible, durable fluoropolymer on very thin cobalt-
chromium alloy struts. In this issue of the Journal (1,2), the
long-term results of 2 pivotal randomized clinical trials
comparing head-to-head EES with paclitaxel-eluting stents
(PES) are presented. Both studies confirm the “clinical
superiority” of EES over PES at 2 years. Notably, EES
appear to be not only more effective (restenosis prevention),
but also safer (thrombosis prevention) than their counter-
parts (1,2). In 1 study, additional benefits of EES were also
demonstrated beyond the first year (2). Can we already
consider second-generation DES qualitatively superior to
first-generation DES? Is the attainable net benefit, clinically
meaningful and cost effective? Is clinical follow-up impor-
tant beyond the first year, or does it matter at all? Shall we
just change our practice?
General Methodological Issues
Follow-up studies of patients treated with DES are plenti-
ful. In many cases, however, major flaws in design are
apparent. Retrospective follow-up strategies allow for
uniquely long follow-up intervals but are vulnerable to
missing data and inadequate quality of the retrieved infor-
mation (6,7). Conversely, in prospective studies, data may
be collected in optimized conditions to maximize their
quality and completeness. Indeed, large, prospective, real-
world registries provide valuable complementary data not
obtainable from randomized studies. However, in registries,
adjusting effect estimates for measured confounders—with
data validation using propensity score calibration—may be
reassuring, but results are never considered as definitive.
Randomized clinical trials remain the best tool to obtain
unbiased estimates of treatment effect. Randomized trials
minimize bias by controlling for potential confounders
(known and unknown) that may affect outcome and distort
the apparent treatment effect (8). Controlled clinical trials
should be pragmatic enough to achieve a balance in the
struggle between external and internal validity. Indeed,
roaming through methodology and inclusion/exclusion cri-
teria may disclose problems in generalizing results from
selected patient cohorts to real-world clinical practice (8).
Patients included in randomized trials tend to have favor-
able outcomes. Reasons for benefit include enrollment of
lower-risk patients, use of highly standardized protocols
with supportive care measures, and special efforts to prevent
treatment hazards (8).
The most frequently used clinical indicator of stent
efficacy is target lesion revascularization (9). Nevertheless,
given the low rates of revascularization after DES, very large
studies are required to demonstrate clinically relevant reduc-
tions in this event. Combined clinical endpoints are also
frequently selected as a primary outcome measure. However,
interpretation of composite outcome measures may be
tarnished by uneven clinical relevance of individual events or
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June 28, 2011:26–9 Second-Generation Drug-Eluting Stentsdivergent effects (10). Accordingly, the potential value of
emerging devices is usually initially addressed by surrogate
angiographic endpoints that guarantee efficacy (9). In a
second phase, larger-scale studies, without systematic late
angiography but with long-term clinical follow-up, are
required to demonstrate noninferiority, or even better,
superiority in safety endpoints.
Small randomized trials provide important mechanistic
insights, but their clinical results may be difficult to interpret.
In these trials, special randomization schemes (different from
1:1) may increase precision of estimates in the new device arm
but may generate imbalances in baseline characteristics (8).
urthermore, devising clinical implications from small studies
esigned to assess surrogate angiographic endpoints may be
isleading. Actually, some of these occurred in SPIRIT II, the
rst randomized study comparing EES with PES (11–13).
his trial may be considered a clear example of unstable
stimates from a trial not powered for clinical endpoints.
ndeed, in this trial, the clinical superiority of EES detected at
year vanished at 2 years, but re-emerged at 3 years (yo-yo
ffect) (11–13). This was further complicated by the occurrence
f a late angiographic and intravascular ultrasound catch-up
henomenon—in an even smaller patient subgroup—that
bscured the interpretation of the 6-month angiographic
rimary endpoint favoring EES (12).
Currently, noninferiority trials are frequently selected to
ompare DES. In noninferiority trials, reference treatment’s
fficacy should be well established, and sample size require-
ents tend to be larger (14). However, given the low
requency of adverse events after DES, relatively large
ifferences are allowed in the noninferiority design to enable
ealistic comparisons. This pays the price of degrading the
onfidence in demonstrating “equivalence” between devices.
ften the noninferiority margin and assay consistency may
e questionable, thus claims regarding efficacy of the new
reatment require cautious interpretation (14). Although
ost of these trials are justified (economic reasons, placebo
bare-metal stent] considered unethical), others may be
riticized for merely studying a new marketable product
“me too” device) (14). Actually, the DES selected as
omparator is of upmost importance because randomized
play-the-winner” initiatives may be selected to increase the
erception of superiority. In this regard, final publications of
ecent randomized studies comparing EES with sirolimus-
luting stents are eagerly awaited.
Finally, only very long-term clinical follow-up of large
andomized studies allows identifying outcome differences
ot apparent in relatively short-term clinical trials (6–8).
owever, even in randomized studies, description of clinical
ourse should document phenomena likely to induce out-
ome changes, as unbalanced concomitant medical treat-
ent (6,8). Furthermore, quality of reporting harms in
andomized studies remains a matter of concern because
afety reporting is frequently neglected (15,16). This prob-
em may be particularly relevant when very-long-term in-
ormation is ascertained. Strict methodological guidelineshave been issued to avoid these deficiencies (16). Assessing
whether clinical results continuously diverge beyond 1 year
may be particularly challenging.
Trial Similarities and Differences
The COMPARE and SPIRIT IV trials represent the
largest and more recent efforts to compare EES with PES in
clinical practice (1,2). Both were high-quality, large ran-
domized clinical trials with a superiority design powered to
detect differences in hard clinical endpoints and with a
pre-specified, long-term clinical follow-up. The primary
endpoint, set at 1 year, included a composite of safety and
efficacy outcome measures. Routine follow-up angiography
was not part of these protocols. By design, allocation conceal-
ment was preserved and ascertainment bias avoided, but, as
occurs in most interventional studies, complete blinding was
not possible. Although lack of masking might theoretically
affect late revascularization indication, consistent results were
found when total and “clinically driven” revascularization rates
were compared. The population pools from which samples
were drawn (patients not enrolled) remained poorly character-
ized. However, in both studies, the attrition rate over time of
enrolled patients was minimal. Finally, SPIRIT IV started only
6 months earlier than COMPARE, so chronologic bias should
not be an issue (1,2).
There are also important design differences between these
trials. Basically, COMPARE was a single-center study that
included complex, real-life patients, whereas SPIRIT IV
was a larger multicenter trial that included relatively selected
patients/lesions. Nevertheless, SPIRIT IV had less restric-
tive inclusion/exclusion criteria than those used in previous
SPIRIT trials. Overall, COMPARE patients had worse
clinical and angiographic baseline characteristics, although,
surprisingly, the prevalence of diabetes was significantly
higher in SPIRIT IV than in COMPARE (32% vs. 18%)
(1,2). Of interest, SPIRIT III demonstrated diverging
clinical results after 1 year, but this late diverging pattern
was not detected in SPIRIT IV (1,17).
Despite differences in trial design, considerable perspec-
tive can be gained by lumping together the results of both
trials with previous data in a new meta-analysis (Fig. 1)
(1–4,12,17,18). Consistent and robust results emerge in favor
of EES. Reasons for the reduced rate of myocardial infarction
after EES remain poorly understood, and their precise ap-
praisal would require patient-level data analyses. Periproce-
dural myocardial infarctions may be reduced by the thinner
struts of EES, leading to superior side-branch patency. Alter-
natively, improved endothelization, as previously demonstrated
“in vivo” (19), may reduce the thrombosis rate. In the com-
bined analysis the risk of stent thrombosis was strikingly
reduced by EES. According to the temporal patterns seen in
the current reports, both mechanisms appear to explain the
reduced rate of myocardial infarction. This meta-analysis
further emphasizes the superior efficacy of EES over PES to
reduce revascularization rates (Fig. 1).
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Second-Generation Drug-Eluting Stents June 28, 2011:26–9In both trials, dual antiplatelet therapy was mandated for
only 12 months (1,2). However, an unexpected, yet relevant,
management difference emerged during follow-up: namely, a
drastic difference in the maintenance of the dual antiplatelet
regimen (70% and 13% in COMPARE vs. 92% and 69% in
SPIRIT IV, at 1 and 2 years, respectively) (1,2). This might
favor SPIRIT IV clinical outcomes. Interestingly, at 2 years,
COMPARE patients treated with EES received less fre-
quently the combined antiplatelet regimen than those assigned
to PES (11.4% vs. 15.4%, p  0.02). If anything, this would
favor PES outcomes unless the dual antiplatelet therapy would
Figure 1 Random-Effects Meta-Analysis of the 2-Year Results o
The 4 trials currently available are SPIRIT II, III, IV, and COMPARE (1–4,11,12,
everolimus-eluting stent(s); I-TLR  ischemia-driven target lesion revasculariza
or probable stent thrombosis according to the Academic Research Consortiumhad been re-initiated following the occurrence of an event. Onthe other hand, equal (1:1) allocation during randomization—as
performed in COMPARE—has the greatest power to detect
differences in clinical outcome. Whether this may explain the
differences beyond the first year that were detected in
COMPARE despite its smaller size remains speculative. The
more complex patient population included in COMPARE,
coupled to the shorter dual antiplatelet regimen, might explain
why minor—yet significant—differences in the clinical efficacy
and safety outcome measures were detected after the first year.
A complex clinical/anatomic scenario may be required to
unravel subtle late clinical differences among DES. Further-
4 Randomized Clinical Trials Comparing EES With PES
). Horizontal axis has a logarithmic scale. CI  confidence interval; EES 
I  myocardial infarction; PES  paclitaxel-eluting stent(s); ST  definitive
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June 28, 2011:26–9 Second-Generation Drug-Eluting Stentsthose used in SPIRIT IV (Taxus Liberté vs. Taxus Express) so
that it is unlikely that this factor would explain the diverging
late clinical outcomes. Further studies will be required to
confirm the continuous divergence of event rates after 1 year
between EES and PES.
Overall, SPIRIT IV might still be considered an efficacy
trial (study under relatively ideal conditions), whereas the
smaller COMPARE trial might be paradoxically labeled as
a pragmatic or effectiveness trial (study under routine
“real-world” circumstances). Although this classification
might be too simplistic, the combined analysis of both trials
(Fig. 1) would take the best of each world since efficacy trials
maximize internal validity (true estimation of the associa-
tion between the intervention and outcome), whereas effec-
tiveness trials emphasize external validity (generalizability of
results). Actually, sample characteristics may be more pow-
erfully correlated with the long-term clinical course than the
compared treatment interventions (6,8).
Finally, stratification (performed in both trials for diabetes)
not only avoids potential imbalances caused by chance in
carefully selected important variables, but also increases the
validity of subsequent subgroup analyses (8). Indeed, stratifi-
cation partially protects against type 1 and 2 errors. This is of
interest, because diabetes presented a significant interaction
with outcome results in both studies, further corroborating
previous observations from earlier EES versus PES compari-
sons. If EES do not confer a distinct benefit over PES in
diabetic patients, the higher prevalence of diabetics in SPIRIT
IV could prevent the recognition of diverging outcomes be-
yond 1 year. Eventually, the way out of this conundrum would
require a specific study in diabetic patients.
Final Remarks
Interventional cardiology is a rapidly evolving field, where new
devices take the position of former generations still under
evaluation. Indeed, the newer generations of EES (Xience
Prime, Promus Element) and PES (Taxus Element), with
advanced platform designs, have already replaced in the cath-
eterization laboratory shelves the stents being compared herein.
Again scientific prudence and genuine safety concerns should
temper overriding enthusiasm. Clinical benefit from technical
advancements should not be impeded, but short-cuts may lead
to serious errors. The field and, above all, our patients, deserve
that high methodological standards are kept in future studies to
ensure a critical, comprehensive, and exhaustive appraisal of
DES long-term results. We should be grateful to Stone et al.
(1) and Smits et al. (2) for performing a systematic late clinical
ollow-up analysis of their patients. Their findings demonstrate
hat second-generation DES help the field to move beyond
omentum.
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